



Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

J.B.Chemicals continues growth march in Q2

Mumbai, October 26, 2010: J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its unaudited standalone financial results for the quarter ended September 2010. The highlights of these results are as under:

HIGH LIGHTS: Q2

- **Net Sales at Rs. 233.14 crores; Up 36.27% Y-o-Y.**
- **EBIDTA at Rs. 60.04 crores, (25.76%); Same in % terms Y-o-Y.**
- **PAT at Rs. 44.61 crores; Up 42.40% Y-o-Y.**
- **EPS - Basic Rs.5.29, Diluted Rs. 5.28; Up 42.32% Y-o-Y.**

HIGH LIGHTS: H1

- **Net Sales at Rs. 392.01 crores; Up 27.99% Y-o-Y.**
- **EBIDTA at Rs. 92.04 crores (23.48%); Up 5.24% Y-o-Y.**
- **PAT at Rs. 65.31 crores; Up 46.89% Y-o-Y.**
- **EPS - Basic Rs.7.74, Diluted Rs. 7.73; Up 46.67% Y-o-Y.**

Operations for the quarter:

The net sales achieved impressive growth of 36.27% as a result of better performance across all segments of the business. The export of formulations registered overall growth of 44% over corresponding quarter in the previous year.

The domestic formulations business too fared well with overall growth of 18%. The company's enhanced focus on domestic formulations business and success of its key brands focus strategy is being reflected in the overall growth as well growth of specific focus brands.

The favorable product mix and cost control helped achieve better profits. The company continued its focus on enhancing efficiencies and was accordingly successful in keeping operating expenses under control despite increase in sales, while interest cost at Rs. 2.04 crores was 40% lower than the corresponding quarter in the previous year.

New Initiatives:

The company has been aggressively pursuing its new initiative of scaling up domestic formulations business and has started making required investments in field force and new products to achieve the growth objective.

During the current quarter, the company launched an anti-hypertensive formulation in US and is on course to file one ANDA this year.

In addition, the company has also started investing in (a) further modernization and efficiency enhancement of the formulations facility at Kadaiya and Panoli, (b) new R&D activities, which will *inter alia* facilitate filing of new products registration applications in important markets, and (c) increase in marketing activities in Russia & CIS countries.

These initiatives are expected to provide new opportunities for future growth and are being funded through internal accruals.

About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and API's. JBCPL exports to many countries worldwide with a strong presence in Russia, Ukraine and the other CIS countries. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D set-up for development of NDDS formulations, filing of DMFs and ANDAs. Its State-of-the-Art Manufacturing facilities are approved by renowned international regulatory authorities.

For more information on JBCPL visit our website at www.jbcpl.com. For more details, you may contact:

M.C. Mehta
Company Secretary- General Manager
J. B. Chemicals & Pharmaceuticals Ltd.
91 22 3045 1311

-- X --

Forward Looking Statements:

This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.